Icagen Finishes Dose Trial for Asthma Drug

Icagen has completed its Phase I multiple-ascending dose trial of senicapoc for the treatment of asthma.

The drug was well tolerated at all tested doses and exhibited pharmacokinetics consistent with once-daily dosing. No serious adverse events were reported, and no patients withdrew from the study. There were no dose-limiting toxicities in any subject.

The company said it expects to initiate a Phase II proof-of-concept clinical trial during the second half of the year.